Medicare Drug Pricing Reform Is A Reality: Here Is What’s On The Agenda
Executive Summary
Congressional Democrats achieved a long-sought goal in passing major legislation to control drug prices in Medicare. A complete lack of Republican support suggests the programs established by the bill will face the same kind of legislative and legal challenges that confronted the Affordable Care Act, which was enacted in a similar manner.
You may also be interested in...
Medicare Price Inflation Rebate List Revisions A Sign Of IRA Implementation Overload?
The Centers for Medicare and Medicaid Services has a lot on its plate and is under intense stakeholder scrutiny as it implements the price control provisions of the Inflation Reduction Act.
Medicare Will Test Payment Model For Accelerated Approvals To ‘Expedite’ Confirmatory Trials
The Center for Medicare and Medicaid Innovation also will develop demonstrations focused on payment arrangements for cell and gene therapy in Medicaid and promoting generic drugs in Medicare Part D.
Medicare Will Pick Up Tab Initially For Lower Part B Coinsurance Resulting From Price Inflation Rebates
Centers for Medicare and Medicaid Services ensures that providers won’t be short-changed if beneficiary cost sharing is lowered because price inflation rebates are applied against drug costs.